{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+interferon+alfa-2a+%28PEG%29&page=3", "query": { "intervention": "Pegylated interferon alfa-2a (PEG)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 92, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+interferon+alfa-2a+%28PEG%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+interferon+alfa-2a+%28PEG%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T02:12:41.092Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00207311", "title": "Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Fatty Liver", "Hepatitis C" ], "interventions": [ { "name": "Xenical, Pegasys, Copegus", "type": "DRUG" }, { "name": "Xenicare Program", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Brooke Army Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2005-08", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2012-02-14", "last_synced_at": "2026-10-12T02:12:41.092Z", "location_count": 1, "location_summary": "Fort Sam Houston, Texas", "locations": [ { "city": "Fort Sam Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00207311" }, { "nct_id": "NCT01329978", "title": "Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" }, { "name": "PEG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 332, "start_date": "2011-03", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-05-26", "last_synced_at": "2026-10-12T02:12:41.092Z", "location_count": 44, "location_summary": "Montgomery, Alabama • Jonesboro, Arkansas • Anaheim, California + 36 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Coronado", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01329978" }, { "nct_id": "NCT00087607", "title": "Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Ribavirin", "type": "DRUG" }, { "name": "Peginterferon alfa-2b (PEG-Intron)", "type": "DRUG" }, { "name": "Peginterferon alfa-2a [Pegasys]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 385, "start_date": "2004-01", "completion_date": "2006-04", "has_results": true, "last_update_posted_date": "2016-07-01", "last_synced_at": "2026-10-12T02:12:41.092Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087607" }, { "nct_id": "NCT00006164", "title": "Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis c", "Cirrhosis, Liver", "Fibrosis, Liver", "Hepatic Cirrhosis" ], "interventions": [ { "name": "Peginterferon alfa-2a + Ribavirin", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1050, "start_date": "2000-06", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2020-05-12", "last_synced_at": "2026-10-12T02:12:41.092Z", "location_count": 11, "location_summary": "Long Beach, California • Los Angeles, California • Denver, Colorado + 8 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006164" }, { "nct_id": "NCT00047879", "title": "Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioma" ], "interventions": [ { "name": "PEG-interferon alfa-2b", "type": "BIOLOGICAL" }, { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2002-10", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2011-10-26", "last_synced_at": "2026-10-12T02:12:41.092Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00047879" }, { "nct_id": "NCT01446250", "title": "Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Boceprevir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 8, "start_date": "2011-12", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2017-01-16", "last_synced_at": "2026-10-12T02:12:41.092Z", "location_count": 2, "location_summary": "Beverly Hills, California • Baltimore, Maryland", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01446250" }, { "nct_id": "NCT01448044", "title": "Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "BMS-790052 (NS5A Replication Complex Inhibitor)", "type": "DRUG" }, { "name": "Placebo matching BMS-790052", "type": "DRUG" }, { "name": "Pegylated-interferon alfa 2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2011-12", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-10-12T02:12:41.092Z", "location_count": 4, "location_summary": "San Clemente, California • Worcester, Massachusetts • Providence, Rhode Island + 1 more", "locations": [ { "city": "San Clemente", "state": "California" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Annandale", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01448044" }, { "nct_id": "NCT01516918", "title": "A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Virus" ], "interventions": [ { "name": "VX-222", "type": "DRUG" }, { "name": "telaprevir", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" }, { "name": "peginterferon-alfa-2a", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 103, "start_date": "2012-02", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2014-10-20", "last_synced_at": "2026-10-12T02:12:41.092Z", "location_count": 28, "location_summary": "Birmingham, Alabama • San Diego, California • Englewood, Colorado + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01516918" }, { "nct_id": "NCT02174172", "title": "A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Interferon alfa-2b", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "PEG-interferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2014-08-18", "completion_date": "2019-11-25", "has_results": false, "last_update_posted_date": "2020-05-12", "last_synced_at": "2026-10-12T02:12:41.092Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02174172" }, { "nct_id": "NCT00084279", "title": "CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "InterMune", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2004-04", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2009-07-03", "last_synced_at": "2026-10-12T02:12:41.092Z", "location_count": 1, "location_summary": "Brisbane, California", "locations": [ { "city": "Brisbane", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00084279" } ] }